2023 net revenue was $79.8M. Raises 2024 adjusted EBITDA view to $0.5M-$1.0M from $0-$0.5M, vs. ($3.9M) in 2023. Stiill sees 2024 gross margin 14%-16%. Projects net sales to grow in the mid-to-high single digits in 2025 and beyond. Rockwell Medical projects gross margin in 2025 to be approximately 20% and reaching above 25% in 2026 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI:
- RMTI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rockwell Medical announces purchase agreement with large health system
- Rockwell Medical expands global distribution in Dominican Republic and Bermuda
- Rockwell Medical price target lowered to $9 from $11 at H.C. Wainwright
- Rockwell Medical Unveils Updated Corporate Insight Presentation